Lung stereotactic radiation therapy: Early results from the Salah Azaiez Institute

##plugins.themes.academic_pro.article.sidebar##

Published Oct 30, 2024
https://doi.org/10.62438/tunismed.v102i11.4926
Download
pdf
Vol. 102 No. 11 (2024): Tunis Med nov 2024

##plugins.themes.academic_pro.article.main##

Alia Mousli
Department of Radiation Oncology, Salah Azaiz Institute, Tunis. Faculty of Medicine of Tunis, University Tunis El Manar, Tunis, Tunisia
Wael Kaabia
Department of Radiation Oncology, Salah Azaiz Institute, Tunis.Tunsia
https://orcid.org/0009-0006-1553-8649
Emna Boudhina
Department of Radiation Oncology, Salah Azaiz Institute, Tunis.Tunsia
Fadoua Bouguerra
Department of Radiation Oncology, Salah Azaiz Institute, Tunis.Tunsia
Amani Yousfi
Department of Radiation Oncology, Salah Azaiz Institute, Tunis. Faculty of Medicine of Tunis, University Tunis El Manar, Tunis, Tunisia
Khedija Ben Zid
Department of Radiation Oncology, Salah Azaiz Institute, Tunis. Faculty of Medicine of Tunis, University Tunis El Manar, Tunis, Tunisia
Lotfi Ben Salem
Department of Medical Physics, Salah Azaiz Institute, Tunis, Tunisia
Ali Essadok
Department of Medical Physics, Salah Azaiz Institute, Tunis, Tunisia
Asma Ghorbel
Department of Radiation Oncology, Salah Azaiz Institute, Tunis. Faculty of Medicine of Tunis, University Tunis El Manar, Tunis, Tunisia
Mounir Besbes
Department of Medical Physics, Salah Azaiz Institute, Tunis, Tunisia
Semia Zarraa
Department of Radiation Oncology, Salah Azaiz Institute, Tunis. Faculty of Medicine of Tunis, University Tunis El Manar, Tunis, Tunisia
Safia Yahyaoui
Department of Radiation Oncology, Salah Azaiz Institute, Tunis. Faculty of Medicine of Tunis, University Tunis El Manar, Tunis, Tunisia
Rim Abidi
Department of Radiation Oncology, Salah Azaiz Institute, Tunis. Faculty of Medicine of Tunis, University Tunis El Manar, Tunis, Tunisia
Chiraz Nasr
Department of Radiation Oncology, Salah Azaiz Institute, Tunis. Faculty of Medicine of Tunis, University Tunis El Manar, Tunis, Tunisia

Abstract

Introduction: Stereotactic Body Radiation Therapy (SBRT) has transformed lung cancer care, delivering precise treatment with minimal harm to healthy tissue.


Aim: This study examined the experience at the Salah Azaiez Institute (SAI) in lung cancer patients.


Methodology: we conducted a retrospective study on patients treated with SBRT from 2019 to 2022. Planification imaging included four-dimensional CT scans and delineation of target volumes and organs-at-risk was done as per international guidelines. Treatment doses were tailored based on tumour location.


Results: A total of 10 cases were included. The male-to-female sex ratio was 4:1, with a median age of 69.5 years. Three had unconfirmed primary lung tumours, while five had inoperable stage I-IIA adenocarcinomas primarily due to compromised respiratory function. Two had oligometastatic lung diseases. All underwent recent thoracic-CT and PET-CT evaluations to exclude pulmonary fibrosis. The median lesion size was 40mm. Karnofsky’s performance status ranged from 70 to 90, with no contraindications to the supine position. Eight out of 10 patients received 8 fractions of 7.5 Gy at the 80% isodose. For that regimen, the D95%, D99%, and Dmax were respectively, 60 Gy, 56 Gy, 73 Gy. All organs-at-risk dosimetric criteria were met. Acute toxicities included worsened coughs in 2 patients and fatigue in 6. After a mean follow-up of 23 months, no rib fractures or haemoptysis were observed, and no local recurrence was reported on the last chest CT scan.


Conclusion: SBRT demonstrates promise for lung cancer treatment, though challenges persist in precise targeting ...(abstract truncated at 250 words).

Keywords:

Stereotactic Body Radiation Therapy, Lung cancer, oligometastatic disease

##plugins.themes.academic_pro.article.details##

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

References

  1. Ricardi U, Badellino S, Filippi AR. Stereotactic body radiotherapy for early stage lung cancer: History and upd oligometastasesated role. Lung Cancer Amst Neth. déc 2015;90(3):388‑96.
  2. Timmerman R, Galvin J, Michalski J, Straube W, Ibbott G, Martin E, et al. Accreditation and quality assurance for Radiation Therapy Oncology Group: Multicenter clinical trials using Stereotactic Body Radiation Therapy in lung cancer. Acta Oncol Stockh Swed. 2006;45(7):779‑86.
  3. Song CW, Glatstein E, Marks LB, Emami B, Grimm J, Sperduto PW, et al. Biological Principles of Stereotactic Body Radiation Therapy (SBRT) and Stereotactic Radiation Surgery (SRS): Indirect Cell Death. Int J Radiat Oncol Biol Phys. 1 mai 2021;110(1):21‑34.
  4. Guckenberger M, Andratschke N, Dieckmann K, Hoogeman MS, Hoyer M, Hurkmans C, et al. ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer. Radiother Oncol J Eur Soc Ther Radiol Oncol. juill 2017;124(1):11‑7.
  5. ICRU Report 83, Prescribing, Recording, and Reporting Intensity-Modulated Photon-Beam Therapy (IMRT) – ICRU [Internet]. [cité 3 oct 2023]. Disponible sur: https://www.icru.org/report/prescribing-recording-and-reporting-intensity-modulated-photon-beam-therapy-imrticru-report-83/
  6. Asamura H. Treatment of choice for stage I non-small cell lung cancer: surgery or radiotherapy? J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. oct 2006;1(8):766‑7.
  7. Okada M, Nishio W, Sakamoto T, Uchino K, Yuki T, Nakagawa A, et al. Effect of tumor size on prognosis in patients with non-small cell lung cancer: the role of segmentectomy as a type of lesser resection. J Thorac Cardiovasc Surg. janv 2005;129(1):87‑93.
  8. Grills IS, Mangona VS, Welsh R, Chmielewski G, McInerney E, Martin S, et al. Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 20 févr 2010;28(6):928‑35.
  9. Kestin L, Grills I, Guckenberger M, Belderbos J, Hope AJ, Werner-Wasik M, et al. Dose-response relationship with clinical outcome for lung stereotactic body radiotherapy (SBRT) delivered via online image guidance. Radiother Oncol J Eur Soc Ther Radiol Oncol. mars 2014;110(3):499‑504.
  10. Bi N, Shedden K, Zheng X, Kong FMS. Comparison of the Effectiveness of Radiofrequency Ablation With Stereotactic Body Radiation Therapy in Inoperable Stage I Non-Small Cell Lung Cancer: A Systemic Review and Pooled Analysis. Int J Radiat Oncol Biol Phys. 1 août 2016;95(5):1378‑90.
  11. Ball D, Mai GT, Vinod S, Babington S, Ruben J, Kron T, et al. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. Lancet Oncol. avr 2019;20(4):494‑503.
  12. Khalifa J, Lerouge D, Le Péchoux C, Pourel N, Darréon J, Mornex F, et al. Radiotherapy for primary lung cancer. Cancer Radiother J Soc Francaise Radiother Oncol. 2022;26(1‑2):231‑43.
  13. Iyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS, et al. Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 11 janv 2018;4(1):e173501.
  14. Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. J Clin Oncol Off J Am Soc Clin Oncol. 1 sept 2020;38(25):2830‑8.
  15. Videtic GMM, Donington J, Giuliani M, Heinzerling J, Karas TZ, Kelsey CR, et al. Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive Summary of an ASTRO Evidence-Based Guideline. Pract Radiat Oncol. 2017;7(5):295‑301.
  16. Escande A, Frey P, Lacornerie T, Mervoyer E, Chargari C, Laurans M, et al. Radiotherapy for patient with cardiac implantable electronic device, consensus from French radiation oncology society. Cancer Radiother J Soc Francaise Radiother Oncol. 2022;26(1‑2):404‑10.
  17. Onishi H, Araki T, Shirato H, Nagata Y, Hiraoka M, Gomi K, et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer. 1 oct 2004;101(7):1623‑31.
  18. Lindberg K, Grozman V, Karlsson K, Lindberg S, Lax I, Wersäll P, et al. The HILUS-Trial-a Prospective Nordic Multicenter Phase 2 Study of Ultracentral Lung Tumors Treated With Stereotactic Body Radiotherapy. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. juill 2021;16(7):1200‑10.
  19. Manyam BV, Verdecchia K, Videtic GMM, Zhuang T, Woody NM, Wei W, et al. Validation of RTOG 0813 Proximal Bronchial Tree Constraints for Pulmonary Toxicity With Stereotactic Body Radiation Therapy for Central Non-small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 1 mai 2020;107(1):72‑8.
  20. Nagata Y, Matsuo Y, Takayama K, Norihisa Y, Mizowaki T, Mitsumori M, et al. Current status of stereotactic body radiotherapy for lung cancer. Int J Clin Oncol. févr 2007;12(1):3‑7.
  21. Bucknell NW, Belderbos J, Palma DA, Iyengar P, Samson P, Chua K, et al. Avoiding Toxicity With Lung Radiation Therapy: An IASLC Perspective. J Thorac Oncol. 1 août 2022;17(8):961‑73.